Monitra Health, a leader in health monitoring technologies, has been awarded US Patent No. 12,109,029 B2 for its groundbreaking wireless cardiac monitoring device. Granted by the United States Patent and Trademark Office on October 8, 2024, the innovation sets a new standard in diagnostic precision and patient convenience.

The patented technology introduces a patch-based cardiac monitoring device for superior diagnostic accuracy and enhanced patient compliance. This wireless device incorporates advanced orientation detection, automatically adapting to its placement on the patient. By intelligently selecting the optimal electrode pairs in real-time, the system ensures consistent signal quality and eliminates errors caused by improper placement.

The device processes bio-potential signals and wirelessly transmits cardiac data to external systems for immediate analysis. Its real-time adaptability and efficient data transmission make it a reliable tool for ambulatory ECG monitoring, addressing conditions such as atrial fibrillation, cardiac arrhythmias, and QT prolongation during clinical trials.

This innovation represents a significant leap forward in cardiac care. It empowers healthcare providers with precise, real-time insights while offering patients a hassle-free monitoring experience.

Monitra Health plans to commercialize the technology, targeting major markets, including the US, UK, and Australia. The company’s advancements are set to transform cardiac monitoring, offering a robust solution for both clinical and research applications.

This patented device reaffirms Monitra’s commitment to developing cutting-edge health monitoring technologies that enhance patient outcomes and streamline healthcare processes.